secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001437749-25-036712
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval for CNM-Au8
--------------------------------------------------------------------------------

- FDA-recommended analyses show statistically significant reductions in NfL (p=0.0373) and GFAP (p<0.05) in ALS patients treated with CNM-Au8.
- CNM-Au8 treatment associated with 73-77% reduction in risk of death at 1 year in HEALEY ALS Platform Trial open-label extension (p=0.0144).
- Company requested Type C meeting with FDA in Q1 2026 for planned NDA submission under accelerated approval pathway.
- Placebo participants who switched to CNM-Au8 showed NfL decline or stabilization, consistent with active arm trajectory.
- Over 1,000 patient years of exposure data show no drug-related serious adverse events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774925036712/0001437749-25-036712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774925036712/clnn20251203_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-036712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer